Pfizer Inc

PFE is in an early Stage 1 base after a terminal decline with repaired short-term EMAs providing support. Despite a long-term downtrend, the active Lockout Rally pattern drives medium-term bullish bias and short-term timing is favorable under the lockout override. Execution is to buy now on continuation above the June stabilization range and rising EMAs, while monitoring for rejection at overhead moving averages.

• ↑High earnings yield and 2.02% dividend yield, $9.8B returned to shareholders.
• ↑Q1 revenue of $14.5B up 7% ex-COVID; adjusted EPS $0.75 beat estimates.
• ↓Patent cliff ahead threatens revenue and margin sustainability.